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In patients referred for allogeneic hematopoietic stem cell transplantation (HSCT), iron overload is frequent
and associated with increased morbidity and mortality. Both the evolution of iron overload after trans-
plantation and its correlation with late posttransplantation events are unknown. We studied 290 patients
undergoing myeloablative allogeneic HSCT between 2000 and 2009. Serum ferritin, transferrin saturation,
transferrin, iron, and soluble transferrin receptor were determined regularly between 1 and 60 months after
HSCT, and values were correlated with transplantation outcome. Ferritin levels peaked in the ﬁrst 3 months
posttransplantation and then decreased to normal values at 5 years. Transferrin saturation and iron behaved
analogously, whereas transferrin and soluble transferrin receptor increased after an early nadir. Landmark
survival analysis showed that hyperferritinemia had a detrimental effect on survival in all periods analyzed (0
to 6 months P < .001; 6 to 12 months P < .001; 1 to 2 years P ¼ .02; 2 to 5 years P ¼ .002). This effect was
independent of red blood cell transfusion dependency and graft-versus-host disease. Similar trends were
seen for other iron parameters. These data show the natural dynamics of iron parameters in the setting of
allogeneic HSCT and provide evidence for a prognostic role of iron overload extending beyond the immediate
posttransplantation period. Interventions to reduce excessive body iron might therefore be beneﬁcial both
before and after HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION orno intervention1 yearafterHSCT failed to showanyeffect on
Allogeneic hematopoietic stem cell transplantation
(HSCT) is often the only curative treatment for malignant and
nonmalignant disorders of the hematopoietic system, but
the procedure is still complicated by considerable morbidity
and mortality. Substantial progress has been made in
controlling therapy-related toxicity by improved treatment
of infections and by reduced intensity of conditioning regi-
mens. Other factors such as iron overload remain uncon-
trolled. The role of iron toxicity as an adverse factor in the
setting of HSCT is incompletely understood. Iron overload,
reﬂected by hyperferritinemia, is frequent in patients
undergoing allogeneic HSCT [1-3], because the pre-
transplantation management of underlying hematological
disorders usually requires repeated red blood cell trans-
fusions. After HSCT, patients depend on continued trans-
fusion support due to bone marrow aplasia induced by
conditioning chemotherapy. Serum ferritin is the marker
routinely used to quantify iron stores. Along with transferrin
saturation and the soluble transferrin receptor (sTfR),
elevated pretransplant ferritin was shown to adversely affect
posttransplantation survival [4,5]. This ﬁnding was inde-
pendent from acute phase reactions as assessed by increased
markers of inﬂammation [6,7].
Our knowledge on the evolution of ferritin and the other
iron parameters after an allogeneic HSCT is scarce. It is
also unknown whether the adverse prognostic effect of
hyperferritinemia before HSCT is conserved in the
posttransplantation period. A small prospective study of 16
subjects with iron overload treated by chelation, phlebotomy,edgments on page 444.
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12.10.012survival [8], possibly due to low patient numbers. To analyze
whether patients might beneﬁt from posttransplantation
interventions to reduce excessive body iron (eg, by chelation
orphlebotomy),weevaluatedhowironparametersevolveafter
transplantation and how parameters of iron overload correlate
with outcome at different time points after transplantation.
DESIGN AND METHODS
Transplantation Procedure
We retrospectively evaluated 290 consecutive patients undergoing
unmanipulated allogeneic HSCT at our center between 2000 and 2009. The
cohort included 168 men and 122 woman with a median age at trans-
plantation of 44 (range, 17 to 70) years. Underlying diseases were acute
myeloid leukemia or myelodysplastic syndrome (n ¼ 150), acute lympho-
blastic leukemia (n ¼ 52), Hodgkin or non-Hodgkin lymphoma and plasma
cell myeloma (n ¼ 44), chronic myeloid leukemia or myeloproliferative
neoplasms (n ¼ 37), and nonmalignant disorders (n ¼ 7). Donors were
predominantly human leukocyte antigen (HLA)-identical siblings or unre-
lated volunteer donors and, rarely, one-antigen mismatched siblings or
HLA-identical parents.
Patients with lymphoma received conditioning with BCNU, etoposide,
cytarabine, melphalan, ﬂudarabine, and single-dose total body irradiation;
patients with aplastic anemia received cyclophosphamide and anti-
thymocyte globulin. All other patients were treated with cyclophospha-
mide and busulfan or cyclophosphamide and total body irradiation with or
without etoposide. Graft-versus-host disease (GVHD) prophylaxis was
composed of cyclosporine A plus either methotrexate or mycophenolate.
Serum iron parameters, including ferritin, transferrin saturation, transferrin,
iron, and sTfR, were determined before HSCT as well as 1, 3, 6, 12, 24, 36, and
60 months posttransplantation. Patient and transplantation characteristics
are summarized in Table 1.
Statistics
The effect of complete iron parameters on transplantation outcome was
analyzed by Kaplan-Meier estimates of overall survival and by cumulative
incidence analysis of relapse and transplantation-related mortality, treating
these endpoints as competing risks. Patients were categorized into groups
with high or low iron parameters according to values above or below
median at each time point. Predictors of transplantation outcome were
further evaluated in multivariable Cox models incorporating ironTransplantation.
Table 1
Patient Characteristics
Characteristic Value
Year of transplant, median (range) 2006 (2000-2009)
Years of follow-up, median (interquartile
range)
5.3 (3.9-7.8)
Age, y, median (range) 44 (17-70)
Disease, %
Acute myeloid leukemia or myelodysplastic
syndrome
150 (52)
Acute lymphoblastic leukemia 52 (18)
Lymphoma or myeloma 44 (15)
Chronic myeloid leukemia or
myeloproliferative neoplasms
37 (13)
Nonmalignant 7 (2)
Sex, %
Male 168 (58)
Female 122 (42)
Stage, %
Early 127 (44)
Intermediate 58 (20)
Advanced 105 (36)
Stem cell source, %
Bone marrow 24 (8)
Peripheral blood 256 (88)
Cord blood 10 (3)
Donor type, %
Identical sibling 165 (57)
One antigen-mismatched sibling 9 (3)
HLA-identical parent 2 (1)
Unrelated 114 (39)
Conditioning, %
Cy/Bu 93 (32)
Cy/TBI 85 (29)
Cy/TBI þ etoposide 78 (27)
BEAM/Flu/TBI 31 (11)
Cy/anti-thymocyte globulin 3 (1)
GVHD prophylaxis, %
CSA/MTX 252 (87)
CSA/MMF 29 (10)
CSA 9 (3)
Cy indicates cyclophosphamide; Bu, busulfan; TBI, total body irradiation;
BEAM; BCNU, etoposide, cytarabine, melphalan; Flu, ﬂudarabine; CSA,
cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil.
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disease type, stage at transplantation as deﬁned in the European Group for
Blood andMarrow Transplantation risk score [9], type of donor, and the year
of transplantation as covariates. Presence of acute and chronic GVHD and
transfusion dependency were coded as time-dependent covariates. All
comparisons were two-sided, and P < .05 was considered signiﬁcant.
RESULTS
Evolution of Iron Parameters after Transplantation
Ferritin was strongly elevated before HSCT with a median
of 1,322 mg/L, peaked 1 to 3 months posttransplantation
(median values, 2,660 and 2,337 mg/L, respectively), and
continuously decreased to reach values within the normalTable 2
Complete Iron Parameters before and after Allogeneic HSCT
Ferritin (mg/L)
median (IQR)
Tf Saturation (%)
median (IQR)
Pretransplantation 1,332 (651-2283) 37 (25-61)
Posttransplantation
1 mo 2,660 (1,139-5,238) 47 (28-87)
3 mo 2,337 (1,163-3,584) 44 (33-81)
6 mo 1,358 (685-2,574) 40 (28-65)
12 mo 1,006 (436-1,881) 36 (27-52)
24 mo 701 (254-1,314) 32 (23-42)
36 mo 346 (120-1,024) 29 (21-37)
60 mo 224 (102-585) 28 (20-32)
Tf indicates transferrin.
Median values and interquartile ranges (IQR) are shown for ferritin, transferrin satu
at 1, 3, 6, 12, 24, 48, and 60 months after HSCT.range at 5 years (224 mg/L, Table 2). Transferrin saturation and
iron analogously peaked in the early posttransplantation
period and subsequently decreased, whereas transferrin
and sTfR increased after an early posttransplantation nadir up
to 5 years. In addition, the course of the sTfR showed a short
peak immediately posttransplantation, presumably reﬂect-
ing expansion of erythropoiesis after transplantation. A
serum ferritin level above 1,000 mg/L, an arbitrary cutoff level
widely used to deﬁne relevant iron overload states, was found
in 62% of patients immediately pretransplantation and in
64%, 51%, 38%, and 12% of patients at 6, 12, 24, and 60 months
posttransplantation, respectively. The posttransplantation
evolution of all iron parameters is depicted in Figure 1.
Because elevated ferritin before HSCT is associated with
increased mortality, normalization of iron parameters in the
posttransplantation course may partially be due to selection
of patients with lower pretransplantation iron burden. To
exclude this bias, we evaluated the evolution of iron
parameters in the patients alive at last follow-up. This pop-
ulation showed an analogous course of ferritin values with
a peak early after HSCT, a steady decrease afterward, and
ultimately normalization, albeit with ferritin values at
a lower level as compared with the total population (peak
values at 1 and 3 months with medians of 790 mg/L and 1286
mg/L, respectively, Supplementary Figure 1). Survivors
treated by phlebotomy at any time of the posttransplantation
follow-up (n ¼ 51) were excluded from this analysis to avoid
confounding of the natural course of iron parameters.
Themediannumberof transfusionsbefore transplantation
was 17 (interquartile range [IQR], 8 to 29; range, 0 to 150) in
121 patients in which complete data were available. Data on
posttransplantation transfusionswereavailable in all patients
and amounted to a median of 6 for the posttransplantation
period 0 to 6 months (IQR, 3 to 15; range, 0 to 69), a median
of 0 for the posttransplantation period 6 to 12 months (IQR,
0 to 0; range, 0 to 59), a median of 0 for 12 to 24months (IQR,
0 to 0; range, 0 to 43), and a median of 0 for 24 to 60 months
(IQR, 0 to 0; range, 0 to 100). The number of pre-
transplantation transfusions correlated signiﬁcantly with
pretransplantation ferritin levels (R2 ¼ .57; P < 106).
Impact of Iron Overload on Transplantation Outcome
Of the 290 patients, 154 (53.1%) were alive at last contact
with a median follow-up of 5.3 years. In accordance with
previously published data [7], Kaplan-Meier analysis of the
full cohort over the entire time of follow-up showed a poor
survival of the patients with pretransplantation ferritin
values elevated above the median (P ¼ .04). To further
analyze at which posttransplantation time point iron over-
load was most detrimental for survival, we performedIron (mmol/L)
median (IQR)
Transferrin (g/L)
median (IQR)
sTfR (mg/L)
median (IQR)
18 (13-26) 1.96 (1.67-2.27) 3.30 (2.10-4.90)
21 (15-35) 1.88 (1.50-2.11) 3.80 (2.63-5.38)
23 (16-32) 1.90 (1.67-2.25) 3.30 (2.55-4.80)
21 (15-30) 1.98 (1.70-2.27) 2.70 (2.00-3.90)
19 (15-26) 2.04 (1.77-2.28) 2.50 (1.90-3.30)
17 (12-24) 2.08 (1.88-2.47) 2.43 (1.81-3.54)
16 (12-22) 2.21 (1.92-2.65) 2.54 (2.10-3.30)
16 (13-19) 2.32 (2.09-2.68) 2.99 (2.00-3.60)
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Figure 1. Time course of complete iron parameters before and after HSCT.
Ferritin (mg/L), transferrin saturation (%), plasma iron (mmol/L), transferrin (g/L),
and the soluble transferrin receptor (sTfR) (mg/L) were serially measured in
patients undergoing allogeneic HSCT after myeloablative conditioning. Values
are presented before starting the conditioning chemotherapy preparing for
S.C. Meyer et al. / Biol Blood Marrow Transplant 19 (2013) 440e444442landmark analysis covering intervals ranging from 0 to 6
months, from 6 to 12months, from 1 to 2 years, and from 2 to
5 years after allogeneic HSCT. Patients alive at the start of
each interval were grouped into those with iron parameters
above or below the median at the start of the respective
interval analyzed (eg, the impact ofþ6 months ferritin levels
above or below the median of 1,358 mg/L was assessed
regarding survival in the time period between þ6 months
and þ12 months; respective medians are shown in Table 2).
This analysis revealed that ferritin levels above the median
continued to have a detrimental prognostic effect on survival
in all time periods after HSCT analyzed (0 to 6 months P <
.001; 6 to 12 months P < .001; 1 to 2 years P ¼ .02; and 2 to
5 years P ¼ .002; Figure 2). Interestingly, just one single
patientwith a ferritin level below themedian diedmore than
6 months posttransplantation.
The detrimental effect of iron overload as assessed by
a pretransplantation ferritin level above the median was
found to operate in all diseases analyzed (5-year overall
survival in patients with acute myeloid leukemia or myelo-
dysplastic syndrome 54% vs 33%; in acute lymphoblastic
leukemia 73% vs 42%; in lymphoma or myeloma 63% vs
42%; in chronic myeloid leukemia or myeloproliferative
neoplasms 72% vs 50%; in nonmalignant disease 100% vs 67%,
for patients with ferritin levels below or above the median,
respectively). Excess mortality in patients with ferritin above
the median was due to signiﬁcantly increased trans-
plantation-related mortality in all posttransplantation
periods evaluated and to increased relapse rates (Figure 3).
A detailed account of the cause of death occurring in the
intervals analyzed in patients with a ferritin level above or
below the median at the start of the respective interval is
given in Table 3. An analogous prognostic effect for ferritin
was seen for transferrin saturation and serum iron values
above the median as well as for transferrin and sTfR values
below the median at the respective time points before and
after HSCT, but their prognostic value was not as strong as
the one of ferritin (Supplementary Figure 2).
The negative prognostic impact of elevated ferritin in the
posttransplantation period is suggestive for a detrimental
effect of excessive body iron stores. Alternatively, hyper-
ferritinemia might be a surrogate marker for underlying
processes causing increased mortality. For example, GVHD
may lead to elevated ferritin by chronic inﬂammatory stimuli
or by increased posttransplantation red blood cell trans-
fusion dependence. Ferritin levels were more elevated in
patients with acute GVHD grades II to IV vs 0 to I (at
3months, 3,064 vs 1,728 mg/L; at 6months,1,500 vs 1,255 mg/
L) and in patients with chronic GVHD (compared with those
without chronic GVHD at 12 months, 1,077 vs 873 mg/L; at 24
months, 771 vs 418 mg/L). To exclude as well as possible a role
of iron overload as an indirect surrogate marker for under-
lying predictors of increased posttransplantation mortality,
we performed multivariable Cox models adjusting for
dependence on red blood cell transfusions, the presence of
acute or chronic GVHD, and disease type and stage. Models
were further adjusted for patient age, type of donor, and the
year of transplantation. This analysis conﬁrmed iron over-
load (as assessed by serum ferritin levels above the median)
as a predictor for increased mortality in all time periods
analyzed. Interestingly, although the absolute risk of dyingHSCTaswell as 1, 3, 6,12, 24, 36, and 60months after allogeneic HSCT. The curve
indicates the median at the respective time points. Interquartile ranges (IQRs)
are indicated by bars. Gray areas represent healthy donor normal ranges.
O
ve
ra
ll S
ur
viv
al
 
0.6
0.0
0.2
0.4
0.8
1.0
P < .001 a
0 1 2 3 4 5 6
Pre-tx ferritin < median 
Pre-tx ferritin > median 
Months Follow-Up 
126 7 8 9 10 11 
P < .001 
6-mo ferritin < median 
6-mo ferritin > median 
12 14 16 18 20 22 24 
P = .02 
12-mo ferritin < median 
12-mo ferritin > median 
24 36 48 60
P = .002 
24-mo ferritin < median 
24-mo ferritin > median 
Ferritin
Figure 2. Time-stratiﬁed Kaplan-Meier survival analysis for ferritin. Patients were categorized according to ferritin values below (dotted line) or above (continuous
line) median.
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overload became more prominent in the later intervals
analyzed (0 to 6 months: hazard ratio [HR], 1.49; 95% conﬁ-
dence interval [CI], 0.96 to 2.33; P ¼ .08; 6 to 12 months: HR,
3.84; 95% CI, 2.89 to 5.10; P< .001; 12 to 24months: HR,14.5;
95% CI, 8.90 to 23.7; P < .001; 24 to 60 months: HR, 17.7; 95%
CI, 9.75 to 32.1; P < .001). Analyses using transferrin, trans-
ferrin saturation, iron, or sTfR showed similar results (data
not shown). However, ferritin proved to be the best predictor
of late mortality after transplantation. Noneiron-associated
variables related to an increased risk of dying were
advanced disease stage, acute GVHD, and use of an HLA-
incompatible donor. In contrast, an underlying disease of
lymphoma/myeloma or chronic myeloid leukemia or
myeloproliferative neoplasms was protective, as was the
development of chronic GVHD.
DISCUSSION
Iron overload is a frequent problem in patients undergoing
HSCT. Its relevance regarding the outcome after allogeneic
HSCT is not conclusively understood. Several studies demon-
strated that hyperferritinemia before allogeneic HSCT has
a negative prognostic impact on overall survival [4,5,7]. The
signiﬁcance of posttransplantation iron overload has not been
evaluated in detail. Further insight into ironmetabolism in the
setting of allogeneic HSCT and into the pathophysiological
effects mediated by different forms of body iron may provide0.0
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Figure 3. Time-stratiﬁed cumulative incidence of relapse and transplantation-related
line) or above (continuous line) median.means to improve the overall outcome of stem cell trans-
plantation. To evaluate the prognostic signiﬁcance of
posttransplantation iron overload, we ﬁrst analyzed the
spontaneous evolution of iron parameters before and after
allogeneic HSCT. Little is known about the natural dynamics of
iron load in themonths and years after HSCT.We analyzed the
course of complete ironparameters and thus provideﬁrst data
of the spontaneous evolution of complete iron parameters up
to 5 years after allogeneic HSCT.
Ferritin, which correlates with stored iron, and transferrin
saturation, which quantiﬁes circulating iron, were highly
elevated immediately before allogeneic HSCT and further
increased in the ﬁrst months after transplantation, as a reﬂec-
tion of red blood cell transfusions administered during
pretransplantation therapy and during the early post-
transplantation phase. Accordingly, we found a clear correla-
tion of pre- andposttransplantation ferritinwith the numberof
red blood cell transfusions. Plasma iron showed an analogous
course as ferritin and transferrin saturation, but its relevance
may be limited, as values are known to be variable and
depending on food intake and time of day. Also, serum iron is
not representative of the forms of body iron mediating toxic
effects such as, for example, nontransferrin-bound iron.
Transferrinand thesTfR, on theotherhand,mirrored thecourse
of ferritinwith decreased values early after transplantation.
Interestingly, ferritin levels peaked in the ﬁrst 1 to 3
months posttransplantation and then continuously12 14 16 18 20 22 24
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mortality. Patients were categorized according to ferritin values below (dotted
Table 3
Causes of Death after Allogeneic HSCT
Ferritin below
Median
Ferritin above
Median
n % n %
0-6 mo
Relapse 7 (32) 16 (31)
Infection 2 (9) 5 (10)
GVHD 7 (31) 12 (24)
Transplant toxicity 5 (23) 15 (29)
Other 1 (5) 3 (6)
6-12 mo
Relapse 1 (100) 14 (66)
Infection 0 2 (10)
GVHD 0 2 (10)
Other 0 3 (14)
12-24 mo
Relapse 0 6 (75)
Infection 0 1 (13)
GVHD 0 1 (13)
24-60 mo
Relapse 0 5 (56)
Infection 0 2 (22)
Other 0 2 (22)
For patients with ferritin values below or above median, causes of death are
shown for the respective time intervals after allogeneic transplantation.
S.C. Meyer et al. / Biol Blood Marrow Transplant 19 (2013) 440e444444decreased to reach values within the normal range at 5 years.
This decline is partly due to a selection of the individuals
with lower ferritin values over time, as patients with
pronounced hyperferritinemia before transplantation show
reduced survival. However, a similar pattern of ferritin levels
emerged when the analysis was restricted to patients alive at
last follow-up who had not undergone phlebotomy. One can
only speculate about potential mechanisms leading to
normalized iron parameters at 5 years posttransplantation.
Increased endogenous mobilization and utilization of
stored and transportable iron along with reduced intestinal
iron absorption may be a mechanism warranting evaluation
in future studies. Recombinant erythropoietin, which would
promote such a utilization process, is only sporadically
applied after allogeneic HSCT at our center.
We next evaluated the signiﬁcance of complete iron
parameters regarding survival after myeloablative allogeneic
HSCT. We found that iron overload had a signiﬁcant negative
impact on survival, with ferritin having the highest
discriminating potential. Importantly, hyperferritinemia was
negatively associated with transplantation outcome during
all intervals analyzed up to 5 years after transplantation. This
ﬁnding suggests that measures to reduce body iron such as
chelation may be beneﬁcial even when initiated after HSCT.
The early posttransplantation period appears suitable for
such interventions as patients are closely followed at regular
visits in the transplantation center.
Thepotentialmechanismsmediating increasedmortality in
patients with hyperferritinemia after allogeneic HSCT remain
speculative andmustbesubject to future studies. First, itwill be
central to evaluate whether excessive body iron stores have
a direct impact on prognosis after HSCT or act merely as
surrogate markers. Although our results are indicative of
a harmful effect of iron overload itself, hyperferritinemia may
still represent a surrogate marker for underlying mechanisms
truly causative for increased mortality. Any observational
analysis of iron overload with transplantation outcomewill be
limited by the fact that the effects of iron overload are inher-
ently hard to separate from effects of underlying processes
leading to iron overload. Only a prospective study in which
patients are randomly assigned to undergo iron-depletingtherapy will be able to deﬁnitively address whether iron over-
load is directly responsible for poor transplantation outcome
and whether removal of iron may be beneﬁcial. Furthermore,
future efforts will need to identify the form of iron responsible
for toxic effects in the peritransplantation setting. Analyses in
the past have evaluated levels of nontransferrin-bound iron in
the acute period of HSCT [10,11]. These studies pointed toward
increased cellular damage due to oxidative stress mediated by
nontransferrin-bound iron, but their signiﬁcance was limited
due to study size. In addition, it is not clear why hyper-
ferritinemia associates with both increased transplantation-
related mortality and increased relapse rates. This ﬁnding,
which is in line with previous analyses on peritransplantation
ironmetabolismat our center [7] but in contrast to theﬁndings
of others [5], highlights the need for elucidation of the
underlying pathophysiological mechanisms mediating
theunfavorableprognostic effectsof excessivebody iron stores.
In conclusion, we found that despite signiﬁcant levels of
iron overload in the early posttransplantation period, iron
parameters normalize over the course of approximately 5
years. During this 5-year period, however, iron overload plays
a critical role as predictor of posttransplantation mortality,
suggesting that efforts to reduce iron overload might be
of beneﬁt bothbefore andafter transplantation. Further studies
arewarranted to dissect thepathophysiologicalmechanismsof
iron metabolism in the setting of allogeneic HSCT.
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